Ovarian Cancer Clinical Trials in St Louis, Missouri

21 studies are recruiting for ovarian cancer in St Louis, Missouri right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

    This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Washington Univ. School of Medicine, St Louis, Missouri
    Locations
    20 in total
    Run by
    Terremoto Biosciences Inc.

    See if you can join NCT07109726 on ClinicalTrials.gov

  2. Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

    This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Washington University School of Medicine in St. Louis, St Louis, Missouri
    Locations
    9 in total
    Run by
    Imunon

    See if you can join NCT06915025 on ClinicalTrials.gov

  3. A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

    This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.

    Stage
    Phase 2
    Ages
    18 to 99
    Site
    Washington University, St Louis, Missouri
    Locations
    74 in total
    Run by
    Incyte Corporation

    See if you can join NCT07023627 on ClinicalTrials.gov

  4. Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

    The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Mercy Hospital St. Louis - David C. Pratt Cancer Center, St Louis, Missouri
    Locations
    192 in total
    Run by
    Incyte Corporation

    See if you can join NCT07214779 on ClinicalTrials.gov

  5. A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

    This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, St Louis, Missouri
    Locations
    67 in total
    Run by
    AstraZeneca

    See if you can join NCT05123482 on ClinicalTrials.gov

  6. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    WashU - Siteman Cancer Center, St Louis, Missouri
    Locations
    26 in total
    Run by
    SystImmune Inc.

    See if you can join NCT06293898 on ClinicalTrials.gov

  7. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Washington University School of Medicine in St. Louis, St Louis, Missouri
    Locations
    39 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06465069 on ClinicalTrials.gov

  8. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

    Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Washington University, St Louis, Missouri
    Locations
    16 in total
    Run by
    A2 Biotherapeutics Inc.

    See if you can join NCT04981119 on ClinicalTrials.gov

  9. A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

    The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Washington University School of Medicine ( Site 0052), St Louis, Missouri
    Locations
    196 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06824467 on ClinicalTrials.gov

  10. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

    This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Washington University, Siteman Cancer Center, St Louis, Missouri
    Locations
    14 in total
    Run by
    NextCure, Inc.

    See if you can join NCT06774963 on ClinicalTrials.gov

  11. A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

    This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Normunity Investigational Site, St Louis, Missouri
    Locations
    18 in total
    Run by
    Normunity AccelCo, Inc.

    See if you can join NCT07182149 on ClinicalTrials.gov

  12. IDOV-Immune for Advanced Solid Tumors

    This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potent…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Washington University School of Medicine, St Louis, Missouri
    Locations
    5 in total
    Run by
    ViroMissile, Inc.

    See if you can join NCT06910657 on ClinicalTrials.gov

  13. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Washington University, St Louis, Missouri
    Locations
    82 in total
    Run by
    Artios Pharma Ltd

    See if you can join NCT04657068 on ClinicalTrials.gov

  14. Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

    This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients w…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Investigative Site #110, St Louis, Missouri
    Locations
    18 in total
    Run by
    MOMA Therapeutics

    See if you can join NCT06545942 on ClinicalTrials.gov

  15. Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

    This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    521, St Louis, Missouri
    Locations
    49 in total
    Run by
    Corcept Therapeutics

    See if you can join NCT06906341 on ClinicalTrials.gov

  16. Lead-212 PSV359 Therapy for Patients With Solid Tumors

    Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

    Stage
    Phase 1
    Ages
    18 to 90
    Site
    Saint Louis University, St Louis, Missouri
    Locations
    11 in total
    Run by
    Perspective Therapeutics

    See if you can join NCT06710756 on ClinicalTrials.gov

  17. Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

    This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence

    Stage
    Not phased
    Ages
    18 and older
    Site
    WU St Louis, St Louis, Missouri
    Locations
    9 in total
    Run by
    M.D. Anderson Cancer Center

    See if you can join NCT05287451 on ClinicalTrials.gov

  18. A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

    The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesotheli…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Washington University, St Louis, Missouri
    Locations
    12 in total
    Run by
    A2 Biotherapeutics Inc.

    See if you can join NCT06051695 on ClinicalTrials.gov

  19. Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

    This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. The aim of this study is to determine the safety and tolerability, as well as to ev…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Washington University School of Medicine in St. Louis, St Louis, Missouri
    Locations
    5 in total
    Run by
    Nerviano Medical Sciences

    See if you can join NCT06930755 on ClinicalTrials.gov

  20. TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

    The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.

    Stage
    Not phased
    Ages
    25 to 50
    Site
    Washington University Medical Center, St Louis, Missouri
    Locations
    66 in total
    Run by
    University Medical Center Nijmegen

    See if you can join NCT04294927 on ClinicalTrials.gov

  21. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, St Louis, Missouri
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.